[A23-86] Sacituzumab govitecan (breast cancer) – Benefit assessment according to §35a Social Code Book V
Last updated 15.02.2024
Project no.:
A23-86
Commission:
Commission awarded on 15.08.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adult patients with unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least 2 additional systemic therapies in the advanced setting
Hint of minor added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://dx.doi.org/10.60584/A23-86
| Project no. | Title | Status |
|---|---|---|
| A21-154 | Sacituzumab (breast cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A24-07 | Sacituzumab govitecan (breast cancer) – Addendum to Project A23-86 | Commission completed |
Federal Joint Committee (G-BA)
2024-02-15 A G-BA decision was published.